Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|A071601||Alliance||Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas||Adult CIRB - Late Phase Emphasis||Available to Open|
|A081801||Alliance||Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO||Adult CIRB - Late Phase Emphasis||Available to Open|
|A081105||Alliance||Randomized Study of Erlotinib Vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A031803||Alliance||Phase II Trial of Intravesical Gemcitabine and MK-3475 (pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|A211601||Alliance||Evaluation of Mammographic Breast Density Effect of Aspirin: A companion study to Alliance Study A011502||Cancer Prevention and Control CIRB||Available to Open|
|A091304||Alliance||A Phase I /Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib In Patients With Locally Advanced/Unresectable And/Or Metastatic Sarcoma||Adult CIRB - Early Phase Emphasis||Available to Open|
|A031501||Alliance||Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (Ambassador) Versus Observation||Adult CIRB - Late Phase Emphasis||Available to Open|
|A091603||Alliance||A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma||Adult CIRB - Late Phase Emphasis||Completed|
|A221504||Alliance||A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer||Cancer Prevention and Control CIRB||Available to Open|
|A211701||Alliance||A Prospective Study to Establish a New Onset Hyperglycemia and Diabetes (NOD) Cohort||Cancer Prevention and Control CIRB||Available to Open|